This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sheridan, C. Immune-checkpoint inhibitors march on, now in combinations. Nat Biotechnol 32, 297–298 (2014). https://doi.org/10.1038/nbt0414-297
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0414-297
This article is cited by
-
BMS bets on targeting IL-8 to enhance cancer immunotherapies
Nature Biotechnology (2016)
-
Immuno-oncology moves beyond PD-1
Nature Biotechnology (2015)
-
Prostate cancer vaccines: the long road to clinical application
Cancer Immunology, Immunotherapy (2015)
-
Big-cap buying bonanza trickles down to small biotech
Nature Biotechnology (2014)